Document:

Exhibit 10.1

 

CORPORATE RESEARCH AGREEMENT

 

THIS CORPORATE RESEARCH
AGREEMENT (this “Agreement”) is effective as of the 8th day of July, 2021 (the “Effective Date”), by and
between Avalon GloboCare Corp. (“AVALON”), a DELAWARE corporation having its administrative headquarters at 4400 Route 9
South, Suite 3100, Freehold, NJ 07728, USA (the “Sponsor”), and the UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH
SYSTEM OF HIGHER EDUCATION, a non-profit, state-related educational institution incorporated under the laws of the Commonwealth of
Pennsylvania and having an office at Office of Sponsored Programs, 3420 Forbes Avenue, 300 Murdoch I Building, Pittsburgh,
Pennsylvania 15260 (the “University”). For the avoidance of doubt, any activities undertaken in connection with this
Agreement at or in connection with the facilities of the University of Pittsburgh, the University of Pittsburgh School of Medicine
(UPSOM), the Immunologic Monitoring and Cellular Products Laboratory (IMCPL), the University of Pittsburgh Medical Center (UPMC) or
the Hillman Cancer Center (HCC) at UPMC shall be deemed to be covered under this Agreement (all such facilities, collectively
“Research Facilities”).

 

WHEREAS, Sponsor desires
to fund the University’s research with respect to a specific research project and research plan agreed upon by University and Sponsor
as set forth in further detail below, and the University agrees to perform such research with Sponsor’s funding;

 

WHEREAS, Yen
Michael S. Hsu, M.D., Ph.D. (“Dr. Hsu”), Associate Professor of Medicine, Division of Hematology/Oncology at the University
of Pittsburgh School of Medicine (UPSOM), Director of Immunologic Monitoring and Cellular Products Laboratory (IMCPL) and Co-Director
of Cellular Therapeutics program at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center (HCC) with an address at
350 Technology Drive, Suite 611, Pittsburgh, PA 15219, USA shall be the University’s principal investigator in conducting the research
for Sponsor (the “Principal Investigator”);

 

WHEREAS, Sponsor
and Dr. Hsu entered into that certain Preliminary Agreement, dated 25 March 2021, and Sponsor hereby acknowledges and agrees that the
Preliminary Agreement did not bind the University under the terms thereof; provided, that notwithstanding the foregoing, the University
and Sponsor hereby acknowledge and agree that any activities undertaken at the Research Facilities in connection with the Preliminary
Agreement shall be deemed to be governed by the terms and conditions of this Agreement as of the Effective Date;

 

NOW, THEREFORE,
in consideration of the mutual promises and covenants contained herein, and intending to be legally bound hereby, the parties agree as
follows:

 

		1.	Scope of Work.

 

		1.1	University agrees to use its reasonable efforts to perform
academic research funded by Sponsor in accordance with the Research Plan entitled “Development of Point-of-care Modular Autonomous
Processing System (“PMAPsysTM” or “PMAPsys”) for Cell and Gene Therapies”
as set out in Exhibit A as attached hereto and made a part hereof (the “Project”). The purpose of this Agreement is
for University to conduct the Project for the design, assembly and validation of Sponsor’s PMAPsysTM platform and system
as well as the completion of the development and validation of the production and manufacturing processes for clinical-grade AVA-011 (the
“Purpose”). AVA-011 is Sponsor’s FLASH- CARTM platform therapeutic candidate that is the subject of pre-clinical
research and development by Sponsor as of the Effective Date. Notwithstanding anything otherwise to the contrary, University acknowledges
and agrees that it shall not modify AVA-011 in any manner without the express prior written authorization of Sponsor.

 

     

     

    

 

		1.2	University shall perform the Project in accordance with academic
standards and all laws and regulations that apply to (a) such standards, (b) the conduct of the Project and (c) the activities undertaken
by University and Principal Investigator hereunder (all such standards, laws and regulations collectively, “Applicable Laws and
Standards”). Sponsor recognizes that the University will not conduct the Project in accordance with U.S. Food and Drug Administration
Good Laboratory Practice regulatory standards (“GLP”), and Sponsor understand and agrees that any Project results generated
may not be used by Sponsor for any filings that require a certification of GLP compliance.

 

		1.3	University certifies that University and Principal Investigator
shall maintain and fully comply with all applicable Accreditations (as defined in Exhibit D) to the extent necessary for University and
Principal Investigator to conduct the Project and fulfill their obligations hereunder as set forth in further detail in Exhibit D attached
hereto and incorporated herein by reference.

 

		2.	Term. This Agreement shall commence on the Effective
Date of this Agreement and shall continue until the second anniversary of the Effective Date; provided, that this Agreement may
be (a) earlier terminated by a party in accordance with Section 10 below or (b) extended for such additional period of time as may be
agreed upon in writing by the parties pursuant to a duly executed amendment hereto (the duration of this Agreement, the “Term”).
Notwithstanding the foregoing, if during any period of the Term, the University is required to temporarily cease its normal operations
due to a federal, state, or local government declaration, the Term and University’s performance obligations hereunder shall be
extended to a time that is commensurate with the University’s temporary cessation of normal operations, plus 10 business days;
and Avalon’s payment obligations and payment terms hereunder shall be similarly tolled and extended for the corresponding time
period.

 

		3.	Payment.

 

		3.1	Sponsor agrees to pay to University the amounts set forth
in the budget in accordance with the payment schedule and other terms set forth in the budget attached hereto and incorporated herein
as Exhibit B (the “Budget”). Such payments shall clearly identify the Principal Investigator and the Project.

 

The parties acknowledge and agree
that the amounts set forth in the Budget shall not be deemed installment payments; and in the event that this Agreement is terminated
for any reason, Sponsor shall have no further payment obligations to University following the effective date of such termination.

 

		3.2	If, at any time during the Term, expenditures are expected
to exceed the total Budget, the University may request additional funds from Sponsor, which Sponsor may elect to provide at its discretion.
In the event that Sponsor elects not to provide additional funds, Sponsor shall have no rights to utilize such portion of the research
results to the extent arising solely from such portion of the research activities that Sponsor has expressly declined to fund by written
notification thereof to the University.

 

		3.3	The University may reasonably reallocate funds within categories
of the Budget to meet the primary objectives of the Project; provided, that the University shall notify Sponsor, and seek Sponsor’s
written approval, thereto prior to any such reallocation. In the event that the Project is completed and there are funds remaining in
the Budget, such unexpended funds shall be refunded to Sponsor upon submission of the University’s final financial statement.

 

		4.	Materials Provided.

 

		4.1	All materials provided for the Project under this Agreement
(the “Materials”) shall be listed on Exhibit C, which shall include the name and amount of the Materials, and the
party providing such Materials (the “Provider”). If no Materials are being provided, Exhibit C shall indicate “none.”

 

    2 

     

    

 

		4.2	All Materials and unmodified derivatives thereof shall remain
the property of the Provider and will be used by the receiving party (the “Recipient”) solely for the Project. Notwithstanding
anything otherwise to the contrary, University acknowledges and agrees that Sponsor Materials existing at the Effective Date or otherwise
provided by Sponsor to University during the term of this Agreement and any intellectual property rights therein or thereto are and shall
be the exclusive property of Sponsor and Sponsor’s preservation of exclusive rights therein are and shall be essential to the business
of Sponsor. The Materials will be returned to the Provider or destroyed by the Recipient, as requested in writing by Provider, at the
end of the Term of this Agreement or upon earlier termination of this Agreement.

 

		4.3	The Materials shall be used with prudence and appropriate
caution in any experimental work. THE MATERIALS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE
OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. Recipient agrees to defend and indemnify the Provider, its trustees, directors, officers,
employees and agents from any and all claims and damages in any way arising from the acquisition, use, storage or disposal of the Materials
by Recipient, unless such claim is solely due to negligence on the part of the Provider.

 

		4.4	Subject to the University limitations set forth in Section
1.2, the Materials will be used in compliance with all applicable statutes and regulations, including the National Institutes of
Health guidelines on the use of animals and recombinant DNA. The Materials may not be used for in vivo testing in human subjects. Materials
derived from human donors may not be transferred with any individual donor-identifying information.

 

		4.5	No option, license, or conveyance of rights, express or implied,
is granted by one party to the other party in connection with any Materials, except the right to use the Materials strictly in accordance
with the terms of this Agreement for the Project.

 

		5.	Equipment.

 

		5.1	Subject to the terms and conditions of this Agreement and
the Sponsor Equipment Loan Agreement (as defined below) relating to the use of Sponsor Equipment (as defined below) by University, Sponsor
will be responsible, at its cost, for the procurement (whether by purchase or lease, at Sponsor’s sole discretion), installation,
regular maintenance and repair of Sponsor’s PMAPsys equipment. Sponsor Equipment will be provided on loan for University to conduct
the sponsored research in accordance with the Research Plan and this Agreement and the Sponsor Equipment Loan Agreement. Upon agreement
of Sponsor, Principal Investigator and University and as set forth in the written Research Plan and the Sponsor Equipment Loan Agreement,
Sponsor Equipment shall include the following instrumentation and equipment: the Maxcyte GTx electroporator, Terumo Quantum, and Cytiva
Sepax. Sponsor and University shall enter into a separate, ancillary agreement governing the loan by Sponsor of Sponsor Equipment to
University and University’s use thereof (the “Sponsor Equipment Loan Agreement”) within 60 days following the Effective
Date of this Agreement to set forth the terms and conditions pursuant to which Sponsor may install and support Sponsor Equipment at University’s
facilities and University may access and use such Sponsor Equipment.

 

		5.2	Except as otherwise provided in this Agreement, the Research
Plan and the Sponsor Equipment Loan Agreement, title to any equipment or supplies (other than Materials provided by or on behalf of Sponsor)
purchased or manufactured by University in the performance of the Project funded under this Agreement shall vest in the University upon
acquisition. Notwithstanding the foregoing, (a) any equipment or hardware provided directly or indirectly by or on behalf of Sponsor
to the University shall be deemed “Sponsor Equipment” and (b) as between the parties, Sponsor Equipment shall be exclusively
owned by Sponsor. Sponsor Equipment shall include without limitation the PMAPsys equipment (including any components thereof) provided
by Sponsor. University shall have no rights to any Sponsor Equipment after the expiration or termination of this Agreement.

 

    3 

     

    

 

		6.	Principal Investigator. The parties acknowledge
and agree that Sponsor’s election to fund the Project is dependent on the appointment of Dr. Yen Michael S. Hsu as Principal Investigator
for the Project and his assumption of responsibilities to direct and undertake the design, development and performance of all Project-related
obligations of University hereunder. If, for any reason, the Principal Investigator is unable to continue to serve as Principal Investigator,
the University may, upon the written request of Sponsor, designate another faculty member who is acceptable to Sponsor to serve as Principal
Investigator of the Project; provided, that Sponsor may elect at its discretion to terminate the Project immediately upon written
notice to University. If a substitute Principal Investigator has not been designated by the University and approved in writing by Sponsor
within thirty(30) days after the original Principal
Investigator ceases his or her services under this Agreement, either party may terminate this Agreement upon written notice thereof to
the other party, subject to the provisions of Section 10 (Termination).

 

		7.	Independent Contractor.

 

		7.1	University is an independent contractor of Sponsor. Sponsor
shall not attempt at any time to exercise any significant degree of control to impede the integrity of the University’s research
efforts and research independence in connection with this Agreement.

 

		7.2	Nothing in this Agreement shall be construed to create a partnership
or joint venture between University and Sponsor, nor shall either party’s employees, servants, agents or representatives be considered
the employees, servants, agents or representatives of the other. Neither party shall have any express or implied right or authority to
assume or create any obligation on behalf of, or in the name of, the other party; or to bind the other party to any contract, agreement
or undertaking with any third party.

 

		7.3	University shall withhold and pay all statutory payroll taxes
and provide any and all employment related insurances, including Workers’ Compensation and Employer’s Liability, for its
employees involved in the Project.

 

		8.	Reports and Records.

 

		8.1	The University shall provide Sponsor with periodic progress
reports on the Project, as specified in the Research Plan attached hereto as Exhibit A; provided, that University shall
provide such periodic progress reports no less frequently than once per calendar quarter during the term of this Agreement. Such progress
reports shall include a detailed description of all Project activities undertaken as of the date of such report, the progress made with
respect to all Project activities with respect to the Research Plan, the rate of spend of the Project funding against the budgeted amounts
set forth in Exhibit B (Budget) hereto and any changes to Project timelines or Project scope or activities anticipated or undertaken
by University. Within thirty (30) days after the expiration of every six-month period during the Term of this Agreement, Principal Investigator
shall provide Sponsor with a written report summarizing all Project data and results obtained during the preceding six-month period.

 

		8.2	University shall provide Sponsor with a final written report
at no additional cost upon completion of the Project or upon earlier termination of this Agreement.

 

		8.3	University shall, at mutually agreed upon times, meet with
Sponsor’s representatives to discuss Project results and reports.

 

		9.	Intellectual Property Rights; ROFO

 

		9.1	Ownership. Ownership of inventions and/or discoveries
developed under this Agreement shall follow inventorship under United States patent laws except as otherwise expressly provided herein.
For purposes of this Section 9.1, (1) “solely” shall mean, with respect to intellectual property made by a party hereto,
without involvement or contribution of any kind by the other party or such other party’s employees or other personnel (including
students) or agents or other third parties contracted by such other party or engaged in a business relationship of any kind with such
other party and (2) “jointly” shall mean, with respect to intellectual property made by the parties hereto, joint involvement
or contribution by both parties or the respective employees (including students) or other personnel or agents or contractors of each
party.

 

		9.2	University shall not file any patent applications or otherwise
seek patent protection claiming any (a) Materials provided by or on behalf of Sponsor or (b) Sponsor Project IP or Sponsor Independent
IP.

 

		9.3	University shall own all rights, title and interest in and
to inventions and/or discoveries developed solely by University employees, students or agents in the performance of the Project under
this Agreement during the term of this Agreement (“University Project IP”); provided, that University hereby grants
to Sponsor a worldwide, irrevocable, non-exclusive, royalty-free, fully paid-up, perpetual right (with the right to sublicense to collaborators
and contractors working on Sponsor’s behalf)
to use University Project IP for commercial purposes research activities and other purposes. The University shall disclose all University
Project IP to Sponsor in writing before the end of the Term of this Agreement. For the avoidance of doubt, University Project IP shall
exclude Sponsor Project IP and Sponsor Independent IP.

 

 

    4 

     

    

 

		(a)	Notwithstanding anything otherwise to the contrary, Sponsor
shall exclusively own all rights, title and interest in and to all inventions (whether or not patentable), discoveries and other intellectual
property of any kind conceived, discovered, created, generated, reduced to practice, developed or otherwise made, solely by Sponsor in
the performance of the Project during this Agreement (collectively, “Sponsor Project IP”); provided, that the University
shall retain a worldwide, irrevocable, non- exclusive, royalty-free right to use such Sponsor Project IP to the extent specifically relating
to the Project only for non-commercial, academic research purposes and for no other purposes.

 

		(b)	Notwithstanding anything otherwise to the contrary, Sponsor shall exclusively
own, as between the parties, all rights, title and interest in and to Sponsor Independent IP (as defined below). “Sponsor Independent
IP” shall mean any and all inventions (whether or not patentable), discoveries, know-how, data, information, technologies and other
intellectual property and intellectual property rights therein or thereto owned or controlled by Sponsor prior to the commencement of
the Project or at any time thereafter to the extent made independently by Sponsor outside the scope of this Project including any intellectual
property or intellectual property rights therein or thereto owned or controlled by Sponsor relating to Sponsor’s therapeutic agents,
compounds, cells, tissues, reagents, standards, samples, materials, products, product candidates, formulations, formulation technologies,
delivery technologies, therapies, services, methodologies, procedures, production or manufacturing processes, other processes, data or
know-how.

 

		(c)	University and Sponsor shall each own an undivided, one-half interest in and to
any inventions (whether or not patentable), data, discoveries and other intellectual property and intellectual property rights therein
or thereto developed jointly by both parties in the performance of the Project during the term of this Agreement (“Co-developed
IP”). Sponsor shall have a right of first offer to exclusively license the University’s interest in Co-developed IP in accordance
with the provisions of this Section 9; provided, that Sponsor as a joint owner of Co-developed IP shall have the right to freely
use, make, sell or otherwise exploit (including without limitation the right to license or sublicense through multiple tiers of sublicense)
Co-developed IP on a non-exclusive basis anywhere in the world without further accounting
to or requiring consent from the University. For the avoidance of doubt, Co-developed IP shall exclude any University Project IP, Sponsor
Project IP or any Sponsor Independent IP.

 

		9.2	Right of First Offer. During the ROFO Period (as defined
below), subject to Public Law 96-517 (codified in 35 U.S.C. §200-212 and implemented in 37 C.F.R. 401) and the terms of this Agreement,
the University hereby grants to Sponsor an exclusive right of first offer (an “ROFO”) to an exclusive royalty- bearing license
to (a) University Project IP and (b) University’s rights, title and interest in and to any Co-developed IP. Such right of first
offer shall remain in effect for ninety (90) days after the date of disclosure to Sponsor (“ROFO Period”). If Sponsor has
not notified University in writing of its desire to enter into license negotiations within such ROFO Period, University shall have the
right, but not the obligation, to license such rights to a third party. The right of first offer granted to Sponsor hereunder shall not
apply to University patents or patent applications issued or filed before the Effective Date of this Agreement. University shall not
offer to a third party more favorable terms when considered in the aggregate than the terms last offered to Sponsor with respect to such
exclusive, royalty-bearing license for a period of one-year following the expiration or termination of this Agreement.

 

		9.3	Should Sponsor notify University of its desire to enter into
license negotiations in accordance with Section 9.2 hereof, the University shall provide Sponsor with a license agreement which shall
include the following negotiable terms:

 

		(a)	Sponsor shall pay to University an execution fee, annual
maintenance payments/minimum royalties, milestones payments (where applicable) and/or reasonable royalty rates on terms to be negotiated;

 

		(b)	University shall retain a royalty-free, non-exclusive right
to use the applicable inventions and/or discoveries for non-commercial education and academic research purposes;

 

    5 

     

    

 

		(c)	Sponsor shall reimburse the University for all applicable
patent prosecution and maintenance out-of-pocket costs actually incurred by University as mutually agreed upon in writing in advance
by the parties in connection with University Project IP or Co-developed IP;

 

		(d)	such license agreement must be finalized and fully executed
within ninety (90) days following Sponsor’s written notification
to University of Sponsor’s exercise of the applicable ROFO pursuant to Section 9.2 or such other longer period of time as may be
mutually agreed upon by the parties in the event both parties are using reasonable efforts to undertake and continue active negotiations
with respect to such agreement (the “Exclusive Option Negotiation Period”);

 

		(e)	Such other reasonable terms and conditions as agreed upon
by the parties.

 

		9.4	Should a mutually acceptable license agreement not be executed
and delivered within the Exclusive Option Negotiation Period, Sponsor shall have no further rights with respect to the ROFO.

 

		9.5	Nothing contained herein shall affect, or be construed to
grant to the other party by implication or otherwise, any rights, title, or interest in or to any (a) pre- existing rights of a party
hereto in intellectual property developed prior to the Effective Date of this Agreement or (b) the rights of a party hereto with respect
to any intellectual property developed independently of this Agreement.

 

		10.	Termination; Effects of Termination.

 

		10.1  	This Agreement may be terminated prior to the expiration of
the Term should any one or more of the following events occur:

 

		(a)	either party provides the other party with ninety (90) days
advance written notice of termination at will for any or no reason;

 

		(b)	a party materially breaches this Agreement, and the non-breaching
party provides the breaching party with thirty (30) days advance written notice of termination and such breach is not remedied within
such thirty (30) day period; or

 

		(c)	immediately by either party should conditions outside of
its control due to a Force Majeure Event (as defined in Section 23 below) render performance an impossibility or impracticability and
result in a cessation of the research Project hereunder for a period of 90 consecutive days or longer (the “Force Majeure Period”).

 

		10.2  	Sponsor shall reimburse the University for any non-cancelable
obligations of University, if any, that have been pre-approved in writing by Sponsor and specifically and solely allocable to Sponsor’s
Project that the University will be contractually required to pay thereafter, notwithstanding the termination (such non-cancellable obligations,
if any, “Sponsor-Specific Non-Cancellable Costs”); provided, that (a) the University shall notify Sponsor of any such
Sponsor- Specific Non-Cancellable Costs prior to committing to assume such non- cancellable obligations and seek Sponsor’s prior
written approval thereof; and (b) upon termination or expiration of this Agreement, University shall confer with Sponsor and the applicable third party vendor to mitigate
and cancel any such outstanding Sponsor-Specific Non-Cancellable Costs.

 

		10.2  	Upon any expiration or termination of this Agreement (a) Principal
Investigator and University shall immediately cease use of all materials, equipment and Confidential Information of Sponsor and Sponsor’s
intellectual property then in University’s possession, unless otherwise instructed in writing by Sponsor and (b) University shall
promptly return to Sponsor at Sponsor’s expense, or destroy at Sponsor’s written request, all Materials, Confidential Information
and Sponsor IP then in University’s possession.

 

		10.3  	Sections 9, 10, 11, 12, 13 (as set forth therein), 14, 15,
and 18-25 shall survive any expiration or termination of this Agreement.

 

    6 

     

    

 

		11.	Limitation of Liability.

 

		11.1  	Sponsor agrees to indemnify, defend and hold harmless the
University, its trustees, officers, employees and agents, against any third party claims of loss, damage or costs (including attorneys’
fees) to the extent actually incurred and arising out of Sponsor’s use of the University’s research data or results generated
from the Project; provided, that the foregoing obligation shall not apply to the extent any such third party claims, losses, damages
or costs result or arise from University’s negligence or willful misconduct. University agrees to indemnify, defend and hold harmless
Sponsor, its Affiliates, directors, officers, employees and agents, against any third party claims of loss, damage or costs (including
attorneys’ fees) to the extent actually incurred and arising out of University’s gross negligence and willful misconducted
in connection with this Agreement.

 

		11.1  	University shall not be liable to Sponsor, its officers, employees,
servants or agents or to any third party for injuries or losses arising out of use of the Project’s research data or results except
to the extent of University’s gross negligence, willful misconduct or fraud. As between the parties, each party shall be responsible
for its own acts and omissions relating to the Project and its use of the Project results.

 

		11.3  	Limitation of Liability. Except with respect to a party’s
indemnification obligations hereunder or a party’s material breach of its confidentiality obligations hereunder or the misuse,
misappropriation or other material violation of a party’s intellectual property rights, neither party will be liable to the other
party with respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable
theory for any indirect, incidental, consequential or punitive damages or lost profits.

 

		12.	Warranty Disclaimers. UNIVERSITY DISCLAIMS AND MAKES NO WARRANTIES OF ANY KIND,
                                                                                    EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING BUT NOT LIMITED TO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE,
                                                                                    MERCHANTABILITY, PATENTABILITY OR THAT SPONSOR’S USE OF THE PROJECT RESEARCH RESULTS WILL BE FREE FROM INFRINGEMENT OF
                                                                                    PATENTS, COPYRIGHTS, TRADEMARKS OR OTHER RIGHTS OF THIRD PARTIES. SPONSOR DISCLAIMS AND MAKES NO WARRANTIES OF ANY KIND, EITHER
                                                                                    EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING BUT NOT LIMITED TO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY,
                                                                                    PATENTABILITY OR THAT UNIVERSITY’S USE OF ANY MATERIALS, DOCUMENTATION, SOFTWARE, HARDWARE, EQUIPMENT OR OTHER TECHNOLOGY
                                                                                    PROVIDED BY SPONSOR IN CONNECTION WITH THE PROJECT OR THIS AGREEMENT WILL BE FREE FROM INFRINGEMENT OF PATENTS, COPYRIGHTS,
                                                                                    TRADEMARKS OR OTHER RIGHTS OF THIRD PARTIES.

 

		13.	Confidentiality.

 

		13.1  	University and Sponsor acknowledge that it may be necessary
to disclose information to each other which each party considers proprietary or confidential in order for the University to perform the
Project. To preserve the proprietary or confidential nature of such information, University and Sponsor agree to use commercially reasonable
efforts to either: (a) clearly mark the term “Confidential Information” upon the information and forward it only to the other
party in writing; or (b) orally disclose to the other party the proprietary or confidential nature of the information, subsequently indicate
the nature of such information in a writing addressed to the other party, and clearly mark the writing or information with the term “Confidential
Information” and deliver it to the other party within sixty (60) days of disclosure; provided, that in each of the foregoing
cases in the event either party declines to so mark such information, the absence of such markings shall not relieve the other party
from its confidentiality obligations under this Agreement with respect to such unmarked information.

 

		13.2  	Neither party shall disclose nor cause to be disclosed any
Confidential Information of the other party without the other party’s prior written consent.

 

    7 

     

    

 

		13.3  	The parties’ obligation of non-disclosure shall not
apply to any or all of information which:

 

		(a)	is in the public domain at the time of disclosure;

 

		(b)	becomes part of the public domain after disclosure through
no fault of the other party;

 

		(c)	is in the other party’s possession at the time of disclosure or is properly
obtained by recipient from a third party with a valid legal right to disclose such information, and such third party is not under a confidentiality
obligation to the disclosing party; or

 

		(d)	is required to be disclosed due to applicable law, regulation or order of court;
provided, that the disclosing party shall use reasonable efforts to obtain confidential treatment thereof by the applicable governmental
entity to which such information is disclosed; or

 

		(e)	is independently developed by a party without direct or indirect reliance on any
Confidential Information of the other party or any Materials of Sponsor.

 

		13.4  	The parties’ obligations regarding Confidential Information
shall survive the expiration or termination of this Agreement for a period of ten (10) years.

 

		14.	Publicity. The Sponsor shall not use the name of
the University or any member of the University’s staff, in connection with any products, promotion, or advertising without the
prior written approval of the University. University shall not use the name of Sponsor in connection with any products, promotion, or
advertising without the prior written approval of the Sponsor.

 

		15.	Publication Rights.

 

		15.1  	University shall have the right to publish the results of
and disseminate information pertaining to the University’s research for the Project conducted under this Agreement, subject to
(a) University’s confidentiality obligations with respect to any Confidential Information of Sponsor and (b) the rights of Sponsor
to seek and obtain protection for its intellectual property rights as set forth in Section 15.2. Sponsor acknowledges the University’s
strong institutional policy favoring the retention of publication rights and dependence upon publication as an essential means of intellectual
exchange.

 

		15.2  	University agrees to submit any proposed publication or presentation of Project results sufficiently
                                                                                   in advance to Sponsor for review and approval prior to publication. University shall identify Sponsor in any publication and may
                                                                                   include Sponsor as a co-author on any publication or presentation of Project data or results when mutually agreeable to the parties
                                                                                   and in accordance with journal publication standards, upon prior written notification thereof to Sponsor and providing Sponsor with
                                                                                   the opportunity to review and comment on any such draft sufficiently prior to publication or presentation thereof. Within thirty
                                                                                   (30) days of its receipt, Sponsor shall advise University in writing of any proprietary or patentable information contained therein
                                                                                   and may, as necessary, formally request the University to delay disclosure of such information. University agrees to refrain from
                                                                                   publishing any such information categorized by Sponsor as proprietary or patentable for a period not to exceed ninety (90) days from
                                                                                   the date of such written request or such additional reasonable amount time as may be mutually agreed to by the parties in writing,
                                                                                   to enable Sponsor to appropriately coordinate with the University to file for the protection of any intellectual or proprietary
                                                                                   property interests. University and Sponsor shall reasonably cooperate in good faith to perfect intellectual or other proprietary
                                                                                   property interests in any Project results or other intellectual property generated in connection with the activities undertaken
                                                                                   herein. Except as set forth in this Agreement, University shall have no other legal obligation to delay publication of results.
                                                                                   Unless otherwise agreed to by Sponsor in writing, University will not disclose Sponsor’s Confidential Information (as defined
                                                                                   above) in any proposed publication or presentation in accordance with Section 13, Confidentiality.

 

    8 

     

    

 

		16.	Independent Inquiry. Nothing in this Agreement shall
be construed to limit the freedom of researchers who are participants in this Agreement, whether paid under this Agreement or not, from
engaging in similar research inquiries made independently under other grants, contracts or agreements with parties other than the Sponsor;
provided, that such University researchers shall not utilize Sponsor’s Confidential Information, Materials and other intellectual
property owned or controlled by Sponsor in connection with such research inquiries with such third parties.. University shall ensure
that all researchers and other personnel who perform the Project or otherwise undertake any activities in connection with this Agreement,
whether or not paid for such research or activities, shall comply with all obligations of University under this Agreement including without
limitation all obligations of University with respect to Sponsor’s Confidential Information, Materials and other intellectual property.
For purposes of clarity, University shall not use Sponsor’s Confidential Information for any purposes other than Sponsor’s
use.

 

		17.	Export Control Regulations. Notwithstanding any
other provision of this Agreement, the parties understand and agree that they are subject to, and agree to abide by, any and all applicable
United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities.
The University’s and Sponsor’s obligations hereunder are contingent on each party’s ability to comply with applicable
United States export and embargo laws and regulations. It is the expectation of the University and Sponsor that the work done pursuant
to this Agreement will constitute fundamental research and be exempt from export control licensing requirements under the applicable
export control laws and regulations. As an institution of higher learning, the University does not wish to take receipt of export-controlled
information except as may be knowingly and expressly agreed to in writing signed by an authorized representative of each of the University
and Sponsor, and for which the University and Sponsor have each made specific arrangements. Sponsor agrees that it will not knowingly
provide or make accessible to University any export-controlled materials (including, without limitation, equipment, information and/or
data) without first informing University of the export-controlled nature of the materials and obtaining from University’s Office
of Sponsored Programs its prior written consent to accept such materials as well as any specific instructions regarding the mechanism
pursuant to which such materials should be passed to University; provided, that University shall promptly provide all such information
in the possession of University to enable Sponsor to make such determination. Sponsor and University each agree to comply with any and
all applicable U.S. export control laws and regulations, as well any and all embargoes and/or other restrictions imposed by the Treasury
Department’s Office of Foreign Asset Controls.

 

		18.	Notice. Any notice or communication pursuant to
this Agreement shall be sufficiently made or given if (a) sent by certified or registered mail, postage prepaid, or by overnight courier,
with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party,
(b) faxed to other party if the sender retains evidence of successful transmission and if the sender promptly sends the original by ordinary
mail, in any event, to the addresses below or as either party shall designate by written notice to the other party or (c) sent via e-mail
to the following e-mail addresses:

 

In the case of University:

 

	For administrative matters:	Office of Sponsored Programs
	 	University of Pittsburgh
	 	3420 Forbes Avenue, 300 Murdoch I Building

                                                   Pittsburgh, PA 15260

	 	Attention:	Clinical/Corporate Contracts SRA00001518
	 	Telephone:	(412) 624-7400
	 	 	 
	For scientific matters:	Yen Michael S. Hsu, M.D., Ph.D.
	 	UPMC Hillman Cancer Center
	 	University
of Pittsburgh School of Medicine

                                                   350 Technology Drive, Suite 611 Pittsburgh, PA 15219

	 	Email:	yeh25@pitt.edu, hsuys@upmc.edu
	 	Office Phone:	(412) 624-1592
	 	Office Fax:	(412) 605-1010

 

    9 

     

    

 

	In the case of Sponsor:	 	 
	 	 	 
	 	Avalon GloboCare Corp.
	 	4400 Route 9 South, Suite 3100
	 	Freehold, NJ 07728, USA
	 	Attention:	 David Jin, M.D.,
Ph.D.
	 	Email:	david@avalon-globocare.com
	 	Office Phone:	(732)
780-4400
	 	Office Fax: 	(732) 780-5600

 

By such notice, either party may change its address or e-mail address
for future notices. Notices mailed shall be deemed given on the date postmarked on the envelope. Notices sent by overnight courier shall
be deemed given on the date received by such courier, as indicated on the shipping manifest or waybill. Notices sent by fax shall be
deemed given on the date faxed. Notices sent via e-mail shall be deemed given on the date the e-mail was received in the recipient’s
e-mail account.

 

		19.	Governing Law. This Agreement shall be governed
by and construed in accordance with the laws of the Commonwealth of Pennsylvania.

 

		20.	Entire Agreement. This Agreement, together with
all attachments and exhibits, constitutes the entire agreement and understanding between the parties and supersedes any prior or contemporaneous
negotiations, agreements, understandings, or arrangements of any nature or kind with respect to the subject matter herein. In the event
of any inconsistency between this Agreement or any attachments and exhibits, the terms of this Agreement shall govern.

 

		21.	Waiver. Neither party waives its right to enforce
any and all provisions of the Agreement at any time during the Term. Either party’s failure to enforce any provision shall not
prejudice such party from later enforcing or exercising the same or any other provision of the Agreement.

 

		22.	Modifications. This Agreement may not be changed,
altered, modified, amended, rescinded, canceled or waived except by a writing executed by authorized representatives the parties.

 

		23.	Force Majeure. No Party will be liable to the other
for any failure or delay in the performance of its obligations to the extent such failure or delay is caused by fire, flood, earthquakes,
other elements of nature, acts of war, terrorism, riots, civil disorders, rebellions or revolutions, disease, epidemics, quarantines,
pandemics, acts of government, a declared state of emergency, delays in visas, changes in laws and governmental policies, or other conditions
beyond its reasonable control following execution of this Agreement. If the performance by either party of any of its obligations under
this Agreement (including making a payment) is prevented by any such circumstances, then such party shall communicate the situation to
the other as soon as possible, and the parties shall endeavor to limit the impact to the Project. The parties agree to mitigate risks
to the Project and personnel, and to amend Project period of performance and milestones if necessary to mitigate such risks as mutually
determined by the parties. Nothing herein shall limit the rights of either party to terminate this Agreement as indicated in Section
10 hereunder.

 

		24.	Binding Agreement on Successors. This Agreement
shall be binding upon each party’s successors and assigns.

 

		25.	Headings. Headings are for convenience of reference
only, and not for interpreting the provisions of the Agreement.

 

		26.	Counterparts. This Agreement may be executed in
counterparts, and by either party on separate counterpart, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

 

[Signature page follows.]

 

    10 

     

    

 

IN WITNESS WHEREOF, the parties have caused
this Agreement to be executed by their respective duly authorized representatives as of the date first above written.

 

	 	SPONSOR: Avalon GloboCare Corp.
	 	 	 

	 	By:	/s/                           
	 	Name:	 
	 	Title:	 
	 	Date:	 
	 	 	 
	 	UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER

                  EDUCATION

 

 

	 	By:	/s/         
	 	Name:	 
	 	Title:	 
	 	Date:	 
	 	 	 
	 	Principal Investigator confirms that he has read and understands this Agreement and agrees to abide by its terms.

 

	 	 /s/         
	 	Principal Investigator
	 	Date:	                      

 

    11 

     

    

 

EXHIBIT A

RESEARCH PLAN/RESEARCH PROTOCOL

 

Within 30 days following the Effective Date (or
such other reasonable period of time as may be agreed by the Parties following the Effective Date), the Parties shall update the Research
Plan, as applicable, and amend this Exhibit A in this Agreement accordingly with the updated Research Plan pursuant to Section 22 (Modifications)
of the Agreement.

 

Title of Research Project:

 

Development of Point-of-care Modular Autonomous Processing System
(PMAPsysTM) for Cell and Gene Therapies.

 

Objective:

 

This sponsored research project will
evaluate the optimal combination of bioreactors and equipment used in clinical manufacturing for RNA anti-CD19 and anti-CD22 CAR-T
(Figure 1). The ultimate goal is to determine the most cost-efficient pre-cGMP workflow to produce experimental anti-CDl9 and
anti-CD22 CAR-T for future development of cGMP manufacturing and IND applications.

 

 

 

    12 

     

    

 

Development of Point-of-care Modular Autonomous Processing System
(PMAPsysTM) for Cell and Gene Therapies.

 

Avalon’s PMAPsysTM is a proprietary
laboratory platform currently under development. The technology is a multi-purpose modular autonomous clinical-grade laboratory system
intended to develop, optimize, and manufacture cell and gene therapies at point-of-use clinical settings. It consists of assembly and
integration of different functional cell processing, production and validation components for generation of specific clinical-grade re-engineered
cell and gene products.

 

The objective of this strategic collaboration
and co-development research project is to establish the PMAPsysTM and bio-production for (not limited to) Avalon’s
cell and gene therapy candidate “AVA-011”, a RNA-based chimeric antigen receptor (CAR)-T for clinical studies. A proposed
work-flow diagram is demonstrated in Exhibit A.

 

The location of this strategic collaboration and co-development project
will be conducted within Principal Investigator’s research area at IMCPL, a registered and accredited facility to conduct innovative product
development and production.

 

    13 

     

    

 

EXHIBIT B

BUDGET

 

University and Principal Investigator shall comply with the budget
principles for the Project as set forth in this Exhibit B:

 

	Expense Items	 	Expense Details	 	Year 1	 	 	Year 2	 	 	Total	 
	Personnel	 	PI (partial salary support) & hiring 
researcher(s)	 	$	102,700	 	 	$	104,909	 	 	$	207,609	 
	Reagents	 	Supplies, Reagents & Core Facility 
Costs	 	$	197,330	 	 	$	195,121	 	 	$	392,451	 
	Other Expenses	 	Conferences, publications, computers, 
software, etc.	 	$	3,000	 	 	$	3,000	 	 	$	6,000	 
	F&A Expenses	 	65%	 	$	196,970	 	 	$	196,970	 	 	$	393,941	 
	Total Budget	 	 	 	$	500,000	 	 	$	500,000	 	 	$	1,000,000	 

 

During the term of this Agreement, Sponsor shall pay to University
the following amounts for use by Principal Investigator solely to conduct the activities set forth in the Research Plan in accordance
with the following payment schedule:

 

	Payment Number	 	Amount Payable by Sponsor 

to University	 	Due Date of Payment
	Payment #1	 	US$125,000	 	
    Within 10 business days following the
    Effective Date

	Payment #2	 	US$125,000	 	1 October 2021
	Payment #3	 	US$125,000	 	1 January 2022
	Payment #4	 	US$125,000	 	1 April 2022
	Payment #5	 	US$125,000	 	1 July 2022
	Payment #6	 	US$125,000	 	1 October 2022
	Payment #7	 	US$125,000	 	1 January 2023
	Payment #8	 	US$125,000	 	1 April 2023

 

Notwithstanding anything otherwise to the contrary (i) the amounts
listed above shall not be deemed installment payments and (ii) in the event this Agreement is earlier terminated by either party for any
reason, Sponsor shall have no obligation to pay any amounts due after the effective date of such termination or otherwise any amounts
for research activities undertaken after the terminating party provides notice of termination to the other party.

 

    14 

     

    

 

EXHIBIT C

SPONSOR MATERIALS

 

Sponsor Materials: AVA-011 Chimeric Antigen Receptor gene expression
vector and other materials provided by Sponsor to University in connection with the Project during the term of this Agreement.

 

    15 

     

    

 

EXHIBIT D

UNIVERSITY ACCREDITATIONS

 

Accreditations maintained as of the Effective
Date by University and Principal Investigator including without limitation in connection with University’s facilities, equipment,
systems, infrastructure, processes, methodologies, procedures, personnel and other resources to the extent relating to the Project and
University’s research and undertakings hereunder (such accreditations, collectively the “University Accreditations”):

 

		1.	FACT: Foundation for the Accreditations of Cellular Therapy
	 	 	 

		2.	CAP: College of American Pathologists
	 	 	 

		3.	CLIA: Clinical Laboratory Improvement Amendments
	 	 	 

		4.	PA DOH: Pennsylvania Department of Health
	 	 	 

		5.	FDA: United States Food and Drug Administration (cGMP, cGTP, cGXP and drug master file and another applicable industry standards and
regulations)

 

University shall acquire and maintain, and fully
comply at all times with all requirements and standards relating to, all Accreditations listed above and all additional Accreditations
required by Sponsor in connection with University’s undertakings under this Agreement. Without limiting any other rights or remedies
of Sponsor, Sponsor shall have the right to terminate this Agreement immediately if University fails to comply with the foregoing obligations.

 

 

 

 

16Exhibit 4.6

 

DESCRIPTION OF CAPITAL STOCK

 

As of the end of the period
covered by the most recent Annual Report on Form 10-K of LiveXLive Media, Inc., its common stock, $0.001 par value per share (the “common
stock”) was registered under Section 12 of the Securities Exchange Act of 1934, as amended. Unless the context otherwise requires,
all references herein to “we”, “our” and “us” refer to LiveXLive Media, Inc.

 

The following description of
the common stock is a summary and does not purport to be complete. A copy of our Certificate of Incorporation, as amended (the “Certificate
of Incorporation”), and our Bylaws, as amended (the “Bylaws”), have been filed as Exhibits 3.1 and 3.3, respectively,
to our Annual Report on Form 10-K for the year ended March 31, 2021 (the “Annual Report”). Our common stock and the rights
of the holders of our common stock are subject to the applicable provisions of the General Corporation Law of the State of Delaware (the
“DGCL”), our Certificate of Incorporation and our Bylaws, as well as some of the terms of our outstanding indebtedness. The
description below of our common stock and provisions of our Certificate of Incorporation and our Bylaws are summaries and are qualified
by reference to the Certificate of Incorporation and our Bylaws, and by the applicable provisions of the DGCL. We encourage you to read
that law and those documents carefully.

 

General

 

Our Certificate of Incorporation
authorizes us to issue up to 10,000,000 shares of preferred stock, $0.001 par value per share, and 500,000,000 shares of our common stock,
$0.001 par value per share.

 

As of July 9, 2021, there were
0 and 77,553,472 shares of our preferred stock and common stock outstanding, respectively.

 

As of July 9, 2021, we had 429
holders of record of our common stock, which excludes stockholders whose shares were held in nominee or street name by brokers. The actual
number of common stockholders is greater than the number of record holders and includes stockholders who are beneficial owners, but whose
shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose
shares may be held in trust by other entities.

 

Common Stock

 

Voting

 

Holders of our common stock are
entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors,
and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in
any election of directors can elect all of the directors standing for election.

 

Dividends

 

Subject to preferences that may
be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be
declared from time to time by our board of directors out of legally available funds.

 

Liquidation

 

In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution
to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference
granted to the holders of any outstanding shares of preferred stock.

 

     

     

    

 

Rights and Preferences

 

Holders of our common stock have
no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock.
The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights
of the holders of shares of any series of our preferred stock that we may designate and issue in the future.

 

Fully Paid and Nonassessable

 

All of our outstanding shares
of common stock are, and the shares of common stock to be issued in this offering will be, fully paid and nonassessable.

 

Preferred Stock

 

Our board of directors has the
authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish
from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares
of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares
of any such series, but not below the number of shares of such series then outstanding.

 

Our board of directors may authorize
the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders
of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit
holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders
of common stock. As of March 31, 2021, there were no shares of our preferred stock outstanding, and we have no current plans to issue
any shares of our preferred stock.

 

Authorized and Unissued Capital Stock

 

DGCL does not require stockholder
approval for any issuance of authorized shares. These additional shares may be used for a variety of corporate purposes, including future
public offerings, to raise additional capital or to facilitate acquisitions.

 

One of the effects of the existence
of unissued and unreserved common stock or preferred stock may be to enable our board of directors to issue shares to persons friendly
to current management, which issuance could render more difficult or discourage an attempt to obtain control of our company by means of
a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive the stockholders
of opportunities to sell their shares at prices higher than prevailing market prices.

 

Warrants

 

As of March 31, 2021, there were 0 warrants
outstanding.

 

Options

 

As of March 31, 2021, we had entered
into agreements to grant options to our employees to purchase 3,921,584 shares of our common stock under the 2016 Equity Incentive Plan,
as amended (the “Plan”), at a weighted average exercise price of $3.74 per share. As of March 31, 2021, we had entered into
agreements to grant options to our non-employees to purchase 25,000 shares of our common stock under the Plan at a weighted average exercise
price of $4.00 per share.

 

For a description of our other
equity grants and awards, see Note 17 – Stockholders’ Equity to our consolidated financial statements included in the Annual
Report.

 

     

     

    

 

Delaware Anti-Takeover Law and Certain Charter
and Bylaw Provisions

 

Delaware Anti-Takeover Statute

 

We are subject to the provisions
of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from
engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following
the date the person became an interested stockholder unless:

 

	 	●	prior to the date of the transaction, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

 

	 	●	upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

 

	 	●	at or subsequent to the date of the transaction, the business combination is approved by our board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.

 

Generally, a business combination
includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested
stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested
stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to
have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that
Section 203 may discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

 

The provisions of Delaware law
and the provisions of our Certificate of Incorporation and Bylaws could have the effect of discouraging others from attempting hostile
takeovers and, as a consequence, they might also inhibit temporary fluctuations in the market price of our common stock that often result
from actual or rumored hostile takeover attempts. These provisions might also have the effect of preventing changes in our management.
It is also possible that these provisions could make it more difficult to accomplish transactions that stockholders might otherwise deem
to be in their best interests.

 

Bylaws

 

Provisions of our Bylaws may delay
or discourage transactions involving an actual or potential change in our control or change in our management, including transactions
in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to
be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our
Bylaws:

 

	 	●	permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);

 

	 	●	provide that the authorized number of directors may be changed only by resolution of the board of directors;

 

	 	●	provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; and

 

     

     

    

 

	 	●	do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose).

 

The amendment of any of these
provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences
and privileges thereto, would require approval by the holders of a majority of our then outstanding common stock.

 

Special Meetings

 

Our Certificate of Incorporation
and Bylaws provide that, except as otherwise required by law, special meetings of the stockholders may only be called by the chairperson
of our board of directors, our Chief Executive Officer or our President (in the absence of a Chief Executive Officer), or by our board
of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the whole board. Only those matters set
forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders.

 

Requirements for Notice of Stockholder Director
Nominations and Stockholder Business

 

If a stockholder wishes to bring
any business before an annual or special meeting or nominate a person for election to our board of directors, our Bylaws contain certain
procedures that must be followed for the advance timing required for delivery of stockholder notice of such nomination or other business
and the information that such notice must contain.

 

Listing

 

Our common stock is listed for quotation
on The NASDAQ Capital Market under the symbol “LIVX.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar
for our common stock is Vstock Transfer, LLC. The transfer agent and registrar’s address is 18 Lafayette Place, Woodmere, NY 11598.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]